Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

pharmafile | August 15, 2019 | News story | Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis 

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s Tremfya (guselkumab), showing that the former met all primary and secondary endpoints in the treatment of moderate to severe plaque psoriasis (PsO).

The 1,027-participant trial is the first to directly compare an IL-17A inhibitor to an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as a primary endpoint to assess their efficacy.

The data revealed that the use of Taltz led to a greater proportion of patients achieving complete skin clearance according to PASI compared to Tremfya, meeting the trial’s primary endpoint. Lilly’s drug also met all of its secondary endpoints, with a greater proportion of patients achieving a PASI score of 75 after two weeks of treatment, and a score of 90 or 100 after four and eight weeks.

“Completely clear skin and rapid relief of symptoms are possible for many people living with moderate to severe plaque psoriasis, and should be two topics dermatologists discuss with their patients,” said Dr Andrew Blauvelt, Dermatologist and President of Oregon Medical Research Center in Portland, Oregon. “Head-to-head data like these are important and will help inform individual treatment goal discussions between healthcare providers and their patients.”

“Lilly’s goal is to raise the treatment bar for people living with psoriasis,” added Dr Lotus Mallbris, Vice President of Immunology Development at Lilly. “And research shows that patients want clear skin and rapid improvements. We’re pleased to see that Taltz helped more people achieve 100% skin clearance compared to Tremfya at week 12. These positive results reinforce that Taltz is an important treatment option for people with this disease.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …

Latest content